Stock Ratings / Health Care / NRSN / dividends

DRMA (34) XTLB (46) MDCX (34) CVKD (34) ⌘ Pro Terminal →

NeuroSense Therapeutics Ltd. (NRSN) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does NRSN pay a dividend and is it safe?

NeuroSense Therapeutics Ltd. (NRSN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.99 -6.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.96

NeuroSense Therapeutics Ltd. (NRSN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRSN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NRSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.99 (-6.57% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NRSN compare to DRMA and XTLB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRSN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRMA (Dermata Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and XTLB (XTL Biopharmaceuticals Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $4.0M). Among the 5-stock peer group, NRSN leads on earnings multiple (N/A) while NRSN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRSN?

▼

Per NRSN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875091), NeuroSense Therapeutics Ltd. generated $0 in revenue, -$11.1M in net income, and -$7.7M in free cash flow against $1.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.96 (-1.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRSN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY NRSN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.49-31.5% Next Q

Q2 (-2Q)

Grade D$2.39-0.8% Next Q

Q3 (-1Q)

Grade E$2.37-16% Next Q

Current

Grade D-$1.99-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NRSN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NRSN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.22) and Max Pain ($2.09) forces dealer call-delta covering toward $26.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRSN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NRSN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRSN)

✓Walkthrough of NRSN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRSN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.82%⚡ TESTING RESISTANCE

2026-11-03O $2.13H $2.13L $1.99C $1.99VOL 20.2K

RES: $3.28SUP: $1.87SMA50: $5.22SMA200: $12.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRSN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRSN Butterfly Map → + Track NRSN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NRSN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRSN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRSN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRSN)

Health Care Rank #614 of 1016 ⚔️ DRMA vs NRSN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRSN vs. DRMA, XTLB, MDCX, CVKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroSense Therapeutics Ltd. (NRSN) ranks #614 by composite RQD confidence (35/100, grade D-) and #961 by equity capitalization ($3.8M). Within this direct 5-issuer industry benchmark cohort, NRSN leads on earnings valuation at N/A trailing P/E, while NRSN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. XTLB currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NRSN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRSN ACTIVE NeuroSense Therapeutics Ltd.	D-	35/100	—	—	-35.0%	-6.57%	$3.8M	Benchmark Subject
DRMA Dermata Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.86%	$3.8M	/drma-vs-nrsn →
XTLB XTL Biopharmaceuticals Ltd.	D	46/100	—	—	—	-8.52%	$4.0M	/xtlb-vs-nrsn →
MDCX Medicus Pharma Ltd.	E	34/100	—	—	-35.0%	-12.56%	$3.6M	/mdcx-vs-nrsn →
CVKD Cadrenal Therapeutics Inc.	E	34/100	—	—	-35.0%	+4.41%	$3.5M	/cvkd-vs-nrsn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001875091

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeuroSense Therapeutics Ltd. (NRSN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.1M, operating cash flow of -$7.7M, and free cash flow of -$7.7M (+24.3% YoY). On the balance sheet, NRSN closed FY2025 with $1.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.1M	-$7.7M	-$7.7M	$1.0M	—
FY2024 (FY)	2024-12-31	$0	-$10.2M	-$10.1M	-$10.1M	$4.6M	—
FY2023 (FY)	2023-12-31	$0	-$10.1M	-$8.4M	-$8.4M	—	—

3. NRSN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NRSN compare to DRMA and XTLB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NRSN?

Where is NRSN trading relative to its 50-day, 200-day, and 52-week technical levels?

NRSN last traded at $1.99 (-6.57% on volume of 20,186 shares), positioning the stock -61.88% below its 50-day simple moving average ($5.22) and -84.32% below its 200-day simple moving average ($12.69). Across its 52-week range of $1.99 to $25.40, NRSN sits at the 0.0% percentile with a 14-day RSI of 24.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.74 to $2.24).

NRSN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does NRSN pay a dividend and is it safe?

NeuroSense Therapeutics Ltd. (NRSN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: NRSN RQD Cockpit NRSN 12M Forecast NRSN Earnings & Move NRSN Dividends & DRIP NRSN Insiders & 13F NRSN Whale Options NRSN Profit Sankey NRSN News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NRSN — NeuroSense Therapeutics Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:41Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NRSN scores 36 out of 100, a D- grade labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Per the RQD pillars, the Fundamental Cash Engine scores 9 / 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 3 / 20, signaling weak institutional accumulation and options positioning. Insider Conviction scores 5 / 20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 9 / 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars point to limited cash-flow support and weak holder conviction; the balance sheet is the strongest-scoring pillar but still only half credit. Any upside case would have to rest on factors outside current cash generation, and the source data does not establish one.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-11.1M	$-11.1M	N/A	$-7.7M	$0.2M	N/A
FY 2024	$0.0M	$-9.9M	$-10.2M	N/A	$-10.1M	$3.4M	N/A
FY 2023	$0.0M	$-12.0M	$-10.1M	N/A	$-8.4M	N/A	N/A

Per the SEC financials, the company reported operating losses and negative free cash flow across all listed periods, with margins at 0% (gross, operating, and net) per the market data. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Cash was reported at $0.2M for FY 2025, down from $3.4M for FY 2024.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items are listed, all tagged "MARKET WIRE" with YELLOW light: a Yahoo Finance UK quote/history page, a TradingView estimates page, a Stock Titan item on a Nasdaq listing test following the $1 share-price rule, a Yahoo! Finance Canada seasonal returns page, a Stock Titan item on a patent filing for a drug combination in treating brain injuries, and a Stock Titan item on planned follow-up study of Lou Gehrig's disease. Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND signal is marked BEARISH with severity 85, a Macro Tailwind Score of 27/100, and a 2.39x Net Liquidity beta (r = +0.16) over a rolling 5-year regression. Per that graph, True Net Liquidity stands at $5,745.73B with a -0.64% 4-week RoC and High-Yield OAS of +2 bps. Key risk watch item: the Nasdaq listing-test coverage, per the news feed.

Open Questions

What revenue, if any, has the company generated, and what is its commercial or licensing model?
What is the outcome and timing of the Nasdaq listing test referenced in the news feed?
What are the current cash balance and debt obligations after FY 2025, given the reported $0.2M cash?
What is the status and value of the drug candidate and patent referenced in the news feed?
Who are the institutional holders and insiders, and have there been recent SEC Form 4 or 13F filings?

NRSN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NeuroSense Therapeutics Ltd. (NRSN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NRSN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

NeuroSense Therapeutics Ltd. (NRSN) stock price, news, quote and history

Yahoo Finance UK report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

NeuroSense Therapeutics Ltd. Estimates – NASDAQ:NRSN

TradingView report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

The $1 share-price rule is met, but NeuroSense still faces another Nasdaq listing test.

Stock Titan report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

NeuroSense Therapeutics Ltd. (NRSN) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Millions are affected by brain injuries each year. NeuroSense filed to patent a drug combination's use in treating them.

Stock Titan report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Earlier findings will shape NeuroSense's planned next study of Lou Gehrig's disease

Stock Titan report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

In a trial, people taking PrimeC had a bigger drop in a nerve-injury marker than people on placebo.

Stock Titan report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

PrimeC could reach patients before marketing approval under NeuroSense (NRSN)'s new advisory deal.

Stock Titan report covering NeuroSense Therapeutics Ltd. (NRSN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRSN Bull vs. Bear Conversation Board — What's Your Call at $1.99?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRSN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.87 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NRSN (D- • RQD 36/100) a Buy at $2.13?

Welcome to the NRSN (NeuroSense Therapeutics Ltd.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.66 (-22.1%)

Spot @ $2.13

Pump the brakes on NRSN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NRSN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NeuroSense Therapeutics Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.66 (+24.9%)

Spot @ $2.13

NRSN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NRSN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.13 (52-wk range $1.99 - $25.40), any beat on forward guidance forces shorts and underweight funds to chase.